^
Association details:
| Biomarker: | EREG overexpression + AREG overexpression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Vectibix (panitumumab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Association between artificial intelligence (AI) -assisted tumor AREG and EREG immunohistochemistry (IHC) and outcomes from anti-EGFR therapy during the routine management of metastatic colorectal cancer (mCRC): An observational cohort study.
Published date:
01/17/2023
Excerpt:
Patients (pts) with available archival FFPE tumor tissue who received panitumumab or cetuximab ± chemotherapy at any time for treatment of mCRC at 8 UK cancer centers were eligible....AREG and EREG positive tumor cells were identified by IHC....110 (24.5%) received concomitant FOLFOX and 304 (67.7%) FOLFIRI. After adjustment for additional prognostic factors, high AREG/EREG expression (n = 360; 80.2%) was associated with significantly prolonged PFS (HR 0.73; 95% CI, 0.56-0.95; p = 0.02), OS (HR 0.66 [0.50-0.86]; p = 0.002), and DCR (OR 1.92 [1.05-3.54]; p = 0.04)....High tumor AREG/EREG expression was associated with significantly prolonged PFS, OS and DCR among a cohort of pts treated with anti-EGFR therapy during routine care of mCRC.
Secondary therapy:
FOLFOX; FOLFIRI
DOI:
10.1200/JCO.2023.41.3_suppl.203
Source:
Title:
Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer
Excerpt:
In RAS wt patients with high ligand expression, panitumumab therapy had a significant effect on PFS (median, 8.3 [interquartile range {IQR}, 4.0-11.0] months for irinotecan with panitumumab vs 4.4 [IQR, 2.8-6.7] months for irinotecan alone; HR, 0.38 [95% CI, 0.24-0.61]; P < .001).
Secondary therapy:
irinotecan
DOI:
10.1001/jamaoncol.2015.6065
